KR880010762A - 소화성궤양의 치료방법 및 치료용 합성물(Composition and Method for Treatment of peptic Ulcers) - Google Patents

소화성궤양의 치료방법 및 치료용 합성물(Composition and Method for Treatment of peptic Ulcers) Download PDF

Info

Publication number
KR880010762A
KR880010762A KR1019880002410A KR880002410A KR880010762A KR 880010762 A KR880010762 A KR 880010762A KR 1019880002410 A KR1019880002410 A KR 1019880002410A KR 880002410 A KR880002410 A KR 880002410A KR 880010762 A KR880010762 A KR 880010762A
Authority
KR
South Korea
Prior art keywords
acids
per day
essential fatty
treatment
acid
Prior art date
Application number
KR1019880002410A
Other languages
English (en)
Inventor
프레드릭 호로빈 데이비드
스튜어트 찰즈
Original Assignee
스테판 제랄드 웨트모어
에파몰 홀딩스 피엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스테판 제랄드 웨트모어, 에파몰 홀딩스 피엘씨 filed Critical 스테판 제랄드 웨트모어
Publication of KR880010762A publication Critical patent/KR880010762A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

소화성궤양의 치료방법 및 치료용 합성물(Composition and Method for Treatment of peptic Ulcers)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (6)

  1. 하루에 1mg 내지 50g, 유리하게는 하루 10mg 내지 1gm을 복용하므로서 소화성궤양의 발생 또는 재발 방지 또는 치료하기 위한 약을 조제하기 위해 18:3 및 n-6열 이상의 산과 18:4 및 n-3열 이상의 산으로부터 선택된 것을 특징으로 하는 하나 또는 그 이상의 필수지방산의 용도.
  2. 제 1 항과 같은 n-6열의 18:3, 20:3, 20:4, 22:4 및 22:5 산과 n-3열의 18:4, 20:4, 20:5, 22:5 및 22:6산들로부터 선택된 것을 특징으로 하는 필수지방산의 용도.
  3. 제 1 또는 제 2 항에 있어서, 상기 산들이 그것들의 염, 아미드, 에스테르, 알콜, 포스포리피드 또는 조제학적으로 배합 가능하며 생리학적으로 등가인 유도체의 용도.
  4. 18:3 및 n-6열 이상의 산과 18:4 및 n-3열 이상의 산들로부터 선택된 하나 또는 그 이상의 필수지방산을 하루에 1mg 내지 50g, 유리하게는 하루에 10mg 내지 1g을 소화성궤양의 재발 또는 발생으로 고통받는 사람이나, 또는 그와 같은 것으로부터 고통을 받을 위험이 있는 사람에게 복용시키므로서 소화성궤양의 재발 또는 발생을 방지 또는 치료하는 것을 특징으로 하는 방지 및 치료법.
  5. 제 4 항에 있어서, 복용하는 산은 n-6열의 18:3, 20:3, 20:4, 22:4 및 22:5 산과 n-3열의 18:4, 20:4, 20:5, 22:5 및 22:6 산들로부터 선택된 필수지방산인 것을 특징으로 하는 필수지방산의 치료법.
  6. 제 4 또는 제 5 항에 있어서, 상기 산들은 그것들의 염, 아미드, 에스테르, 알콜, 포스포리피드 또는 조제학적으로 배합가능하고 생리학적으로 등가인 유도체인 것을 특징으로 하는 치료법(treatment).
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880002410A 1987-03-09 1988-03-08 소화성궤양의 치료방법 및 치료용 합성물(Composition and Method for Treatment of peptic Ulcers) KR880010762A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB8705459 1987-03-09
GB878705459A GB8705459D0 (en) 1987-03-09 1987-03-09 Treatment of peptic ulcers

Publications (1)

Publication Number Publication Date
KR880010762A true KR880010762A (ko) 1988-10-24

Family

ID=10613574

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880002410A KR880010762A (ko) 1987-03-09 1988-03-08 소화성궤양의 치료방법 및 치료용 합성물(Composition and Method for Treatment of peptic Ulcers)

Country Status (12)

Country Link
EP (1) EP0283140B1 (ko)
JP (1) JPS63230631A (ko)
KR (1) KR880010762A (ko)
AT (1) ATE81972T1 (ko)
AU (1) AU608571B2 (ko)
CA (1) CA1302892C (ko)
DE (1) DE3875637T2 (ko)
ES (1) ES2052702T3 (ko)
GB (1) GB8705459D0 (ko)
GR (1) GR3006434T3 (ko)
IE (1) IE62293B1 (ko)
ZA (1) ZA881596B (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
GB8916734D0 (en) * 1989-07-21 1989-09-06 Efamol Holdings Pharmaceutical and dietary uses of fatty acids
AU711482B2 (en) * 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications
SE0202188D0 (sv) 2002-07-11 2002-07-11 Pronova Biocare As A process for decreasing environmental pollutants in an oil or a fat, a volatile fat or oil environmental pollutants decreasing working fluid, a health supplement, and an animal feed product
EP2295529B2 (en) 2002-07-11 2022-05-18 Basf As Use of a volatile environmental pollutants-decreasing working fluid for decreasing the amount of pollutants in a fat for alimentary or cosmetic use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ205076A (en) * 1982-08-09 1985-04-30 Univ California Protecting and healing gastro-duodenal mucosa and the liver of mammals using a fatty acid
JPS5962522A (ja) * 1982-08-09 1984-04-10 ザ・リ−ジエンツ・オブ・ザ・ユニバ−シテイ・オブ・カリフオルニア 胃十二指腸粘膜と肝臓を保護したり、治癒するための方法及び組成物
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
AU4595985A (en) * 1984-08-10 1986-02-13 Sentrachem Limited Cancer treatment
GB8507058D0 (en) * 1985-03-19 1985-04-24 Efamol Ltd Pharmaceutical & dietary compositions

Also Published As

Publication number Publication date
IE880552L (en) 1988-09-09
EP0283140A3 (en) 1989-07-26
DE3875637T2 (de) 1993-04-08
CA1302892C (en) 1992-06-09
DE3875637D1 (de) 1992-12-10
ATE81972T1 (de) 1992-11-15
JPS63230631A (ja) 1988-09-27
EP0283140B1 (en) 1992-11-04
AU608571B2 (en) 1991-04-11
AU1253288A (en) 1988-09-08
GR3006434T3 (ko) 1993-06-21
GB8705459D0 (en) 1987-04-15
EP0283140A2 (en) 1988-09-21
ES2052702T3 (es) 1994-07-16
ZA881596B (en) 1988-08-20
IE62293B1 (en) 1995-01-25

Similar Documents

Publication Publication Date Title
ES2032382T3 (es) Metodo para preparar un medicamento para la prevencion o tratamiento de la endometriosis.
NO940277L (no) Triglycerider og blandinger av slike
DE3172223D1 (en) Edible, pharmaceutical compositions and processes for making thereof
ATE79544T1 (de) Zusammensetzungen zur behandlung von hypercholesterinaemie.
DE3856435T2 (de) Verwendung von Gallsäure-aktiviertem Lipase als Diätsupplement
DE68905863D1 (de) Zusammensetzungen essentieller fettsaeuren.
ATE31625T1 (de) Pharmazeutisches mittel zur behandlung des diabetes mellitus.
IT8423086A1 (it) Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica
ATE96313T1 (de) Fettsaeure-zusammensetzungen.
EP0151989A3 (en) Means for the treatment of cardiac diseases
DE3862337D1 (de) Pharmazeutische zubereitungen, die ester oder amide als wirkstoffe enthalten.
IT1170214B (it) Composizione farmaceutica per la cura delle arteriopatie periferiche
IT1187687B (it) Composizioni farmaceutiche contenenti come principi attivi flavanolignani e fosfolipidi
ATE135909T1 (de) Verfahren zur behandlung von akne
NO306762B1 (no) Anvendelse av lanolinderivater sammen med polyetylenglykoletere, blanding derav og transdermalt terapeutisk system
KR880010762A (ko) 소화성궤양의 치료방법 및 치료용 합성물(Composition and Method for Treatment of peptic Ulcers)
NO891220L (no) Middel som inneholder salicylsyre for behandling av lepidose.
MX9203374A (es) Composicion farmaceutica que contiene l-alfa-glicerofosforilcolina.
JPS5326316A (en) Drug containing active vitamin d3 derivatives and its preparation
IT1224250B (it) Associzione del depiprazolo con la morfina
ATE87482T1 (de) Pharmazeutische praeparate zur behandlung von zereberalen psycho-organischen syndromen.
ES2163450T3 (es) Utilizacion de benzidamina en el tratamiento de estados patologicos causados por tnf.
DE3483285D1 (de) Etofenamat-zubereitung.
JPS5251362A (en) Preparation of optically active pyrrolidine derivatives
SE8800101D0 (sv) Anvendning av essentiella fettsyror for framstellning av ett preparat for behandling av eksem

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application